Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2024Diabetes Obesity and Metabolism

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJingchuan GuoHTHuilin TangHSHui Shao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/68e58decb6db643587529ad7https://doi.org/10.1111/dom.15943
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors2021 · 58 citations
  2. 2Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review2019 · 37 citations
  3. 3Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease2023 · 13 citations
  4. 4The Impact of Type 2 Diabetes in Parkinson's Disease2022 · 131 citations
  5. 5Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study2019 · 124 citations